Dermata Therapeutics (DRMA)Officer bought ~$1.3K

~$1.3K

Approx. value · 1,000 sh @ $1.27

1,012

Holds after · shares reported

Traded

Feb 17, 2026

Filed

Mar 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 23, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Jan 30, 2026Company filing · Form 8-K · Auditor changeChanged its auditor“On January 30, 2026, Dermata Therapeutics, Inc. (the “Company”) notified Baker Tilly US, LLP (formerly Moss Adams LLP) (“Baker Tilly”) that Baker Tilly would be dismissed as the Company’s independent registered public accounting firm.”
3. Feb 17, 2026 · this disclosureInsider · 6 days before an 8-KOfficer purchased ~$1.3K of DRMA shares in the open market

What came next

1. Feb 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 23, 2026, Mary Fisher provided Dermata Therapeutics, Inc. (the “Company”) with notice of her resignation from the Board of Directors (the “Board”), including from her role on any committees thereof, effective March 31, 2026.”
2. Mar 26, 2026Company filing · Form 8-K · ResultsReported its results
3. Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
4. May 27, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 27, 2026, Dermata Therapeutics, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, shareholders approved an amendment to the Company’s 2021 Omnibus Equity Incentive Plan (the “ 2021 Plan ”) to increase the number of shares available for issuance thereunder to 402,214 shares (the “ Plan Amendment ”).”
5. Jun 16, 2026InsiderDirector sold ~$13 of DRMA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dermata Therapeutics

OQRO holds no insider, Congress, fund or contract record for Dermata Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DRMA page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dermata Therapeutics

• SEC Form 4Jun 16, 2026

Everything OQRO holds on this company is on its DRMA page.